SER 109

Drug Profile

SER 109

Alternative Names: SER109

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Seres Health
  • Developer Seres Therapeutics
  • Class Anti-infectives; Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Clostridium infections

Most Recent Events

  • 12 Jun 2017 The US FDA designates ECOSPOR III trial a phase III trial for Clostridium infections (Recurrent)
  • 12 Jun 2017 Seres Therapeutics initiates the pivotal phase III ECOSPOR III trial for Clostridium infections (Recurrent) in USA
  • 01 Jun 2017 Phase-III clinical trials in Clostridium infections (Recurrent, Treatment-experienced) in USA (PO) (NCT03183141)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top